Search
Search
ARVO: 2023
Carl Danzig, MD
Show Description +
Carl Danzig, MD, provides a brief review of a GATHER2 post-hoc analysis that found a decreased proportion of patients who had a greater than 10-, 15-, or 20-letter loss when treated with avacincaptad pegol (Zimura, Iveric Bio) versus sham.
Posted: 5/15/2023
Carl Danzig, MD
Carl Danzig, MD, provides a brief review of a GATHER2 post-hoc analysis that found a decreased proportion of patients who had a greater than 10-, 15-, or 20-letter loss when treated with avacincaptad pegol (Zimura, Iveric Bio) versus sham.
Posted: 5/15/2023
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2023.
Please log in to leave a comment.